RandyW Posted November 21, 2008 Share Posted November 21, 2008 LONDON (MarketWatch) -- Astrazeneca PLC (AZN:astrazeneca plc sponsored adr News, chart, profile, more Last: 34.74-2.10-5.70% AZN 34.74, -2.10, -5.7%) Wednesday said its experimental lung-cancer drug Zactima showed clinical benefits in lung cancer patients in combination with chemotherapy, according to the results of three Phase III studies. The U.K.-based drugmaker said one large study, named ZODIAC, showed advantages for Zactima in combination with chemotherapy, although a smaller combination in a study called ZEAL did not show statistical significance. But both combination studies showed that adding Zactima to chemotherapy significantly improved the 'Objective Response Rate' which measure tumor shrinkage, the company said in a statement. A monotherapy study comparing Zactima, whose generic name is vandetanib, with erlotinib, or Tarceva, a lung-cancer drug made by Roche Holding AG (ROG.VX), did not demonstrate statistical significance in prolonging 'progression free survival' which measures the time during and after treatment when the disease does not get worse. Company Web site: www.astrazeneca.co.uk -0- Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.